IndustryCompany release

Fortress Biotech Q3 revenue rises 9% to $19.2M as Oaktree facility is repaid

🇺🇸 Fortress Biotech, Inc. (FBIO) · Fri 13 Nov 2026

The company reports a $7.9M net loss for the quarter, clears its Oaktree balance and adds a Phase 2 IBS-D asset licensed from Cedars-Sinai.

Fortress Biotech reported third-quarter 2026 results on 13 November, with net revenue of $19.2M, up 9%. Most of the revenue came from Emrosi, a product marketed by its subsidiary Journey Medical. Net loss attributable to common stockholders was $7.9M.

On financing, the company repaid the remaining $15M balance of its credit facility with Oaktree in September, removing that debt from its balance sheet.

On the pipeline side, a Fortress subsidiary has licensed FB-607 from Cedars-Sinai for irritable bowel syndrome with diarrhoea (IBS-D). The candidate is currently in Phase 2 development.

Fortress also noted developments at partner companies. Japan approved anselamimab in September for systemic kappa light chain amyloidosis. Separately, Crystalys raised a $130M Series B round to support dotinurad in gout.

The summary available does not include further detail on Emrosi sales, FB-607 development timelines or the terms of the licence.

What it means for your team

  • Market-access teams may wish to track Emrosi, which the company identifies as the main driver of revenue growth.
  • Regulatory teams can note the September approval of anselamimab in Japan for systemic kappa light chain amyloidosis, a partner-led milestone.
  • FB-607 for IBS-D is at Phase 2, so it remains early-stage and is not yet a near-term regulatory event.
  • Crystalys's $130M Series B marks continued funding for dotinurad in gout, though the available information gives no regulatory status.

Company's press release (SEC filing): Fortress Biotech, Inc. ↗

Article written by VigiEye from the official source (Fortress Biotech, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →